Cortexyme Inc.   Report issue

For profit Phase 3
Founded: San Francisco CA United States (2012)

Organization Overview

First Clinical Trial
2017
NCT03331900
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cortexyme Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

atuzaginstat (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1